Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018

Summary

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediate a sustained cardioprotective function during cardiac ischemia.

It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 1, 8, 4 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Central Nervous System, Dermatology, Hematological Disorders, Male Health, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glaucoma, Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Arthritis, Asthma, Atopic Dermatitis, Chemotherapy Induced Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Glomerulonephritis, Hepatocellular Carcinoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Irritable Bowel Syndrome, Kidney Fibrosis, Lupus Erythematosus, Melanoma, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Ocular Hypertension, Open-Angle Glaucoma, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Pulmonary Fibrosis.

The latest report Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents:

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
Can-Fite BioPharma Ltd
Adenosine Receptor A3 (ADORA3) - Drug Profiles
ACN-1052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Piclidenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities
Feb 12, 2018: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
Jan 25, 2018: Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
Dec 18, 2017: Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson
Nov 27, 2017: Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson
Oct 30, 2017: Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis
Oct 17, 2017: Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis
Oct 16, 2017: Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.
Oct 09, 2017: Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017
Aug 23, 2017: Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
Aug 09, 2017: Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer
Aug 07, 2017: Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
Jul 17, 2017: Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Can-Fite BioPharma Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

Companies Mentioned:
Can-Fite BioPharma Ltd

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

This person cannot share the publication (or any information contained therein) with any other person or persons.

Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.

Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

No. 1101, Golden Square, 3rd Floor, 24th Main, J P Nagar, 1st Phase,